Replies to post #8798 on Quanta Inc (fka QNTA)

[groverdongles]

It’s just not worth having money in this stock right now in my opinion. They’re likely adding/diluting shares based on the daily sell volume. They lost investors after they announced the 6x raise in A/S, and the FDA update was worse than anticipated. There’s no hype, no anticipation of news, and that’s everything in OTC stocks. When they change the ticker name and offer a concrete update on what they’re actually doing with the share structure, this might move again. But for now, this is radioactive and I’m staying far away.

[falon]

This stock is not headed down a dead end.

It is on a road trip with down the FDA freeway with detours along the way. However QNTA will reach their intended destination which is IND application approval.

Detour

Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.

Will there be more detours?

We will find out after QNTA submits the two addition toxicology studies.

We have people in our camp that should help to get us through the FDA approval process:

“Given the ever-changing landscape of COVID-19, we are pleased that the FDA recognizes that our original proposed study was a proof-of-concept design under our original Pre-IND submission,” said Christina DiArcangelo, CEO and Founder of Affinity Bio Partners, a contracted clinical consultant for Medolife.

DiArcangelo has 24 years of experience in the global biotechnology, pharmaceutical, device, and nutraceutical industries and has worked on products that have received FDA approval on 25 pharmaceutical drugs.